We are proud to have participated in the MGFA Scientific Session at #AANEM. To learn more about the retreatment data we presented: bit.ly/3VmWmWl We look forward to topline results from our Phase 3 AURORA trial in 1Q27. #CellTherapy #Autoimmunity #RareDisease

Meet us during the MGFA Scientific Session at #AANEM in Orlando and attend our presentation of Descartes-08 retreatment data following a full treatment course in the Phase 2 portion of the study supporting our ongoing Phase 3 AURORA trial in #MG. bit.ly/4ALehX5

Tune in tomorrow at 1:30 pm ET to hear our fireside chat at the H.C. Wainwright & Co. 28th Annual Global Investment Conference. Listen to the webcast here: bit.ly/3UMAenY #celltherapy #autoimmunity

Tune in tomorrow at 3:55 pm ET to hear our fireside chat at the Cantor Global Healthcare Conference. Listen to the webcast here: bit.ly/4xjyXT8 #celltherapy #autoimmunity

Today, we reported second quarter 2026 financial results and provided a business update. Read the full press release here: bit.ly/3RvJdsE #celltherapy #autoimmunity

We’re excited to announce a strategic licensing agreement with WestGene Biopharma to advance the development of novel in vivo chimeric antigen receptor T-cell (CAR-T) therapies in #autoimmune diseases. Read more: bit.ly/4vxjVZi

We are excited to announce we entered into an agreement with K2 HealthVentures to provide a credit facility of up to $150 million, extending cash runway into 2028. We also announced progress and updated timelines for all ongoing trials. Read more: bit.ly/4dNkOpA

Tune in tomorrow at 3:00 pm ET to hear our fireside chat at the H.C. Wainwright 4th Annual BioConnect Nasdaq Investor Conference. Listen to the webcast here: bit.ly/4wmjkLl #celltherapy #autoimmunity

Our team is on the ground at the @ASGCTherapy 2026 Annual Meeting kicking off tomorrow. Come see our posters to hear more about our work in #myastheniagravis. #celltherapy #autoimmunity

Today we reported first quarter 2026 financial results and provided a business update. Full press release: bit.ly/425CDL2 #celltherapy #autoimmunity

We attended the @AANmember 2026 Annual Meeting this week! We had a lovely time connecting with researchers and doctors from around the world on new and exciting potential therapies for #MG. Learn more about our Ph3 AURORA trial: bit.ly/4mK8Xwi #CellTherapy #Autoimmune

Our team is on the ground at the @AANmember 2026 Annual Meeting kicking off tomorrow. Come see our poster to hear more about our work in #myastheniagravis. #celltherapy #autoimmunity

Our team is on the ground at the @AANmember 2026 Annual Meeting kicking off tomorrow. Come see our poster to hear more about our work in #myastheniagravis. #celltherapy #autoimmunity

Our team attended the @MyastheniaOrg National Patient Conference this week! It was great to meet and connect with patients, families, advocates and #MG experts throughout the event. To learn more about our Phase 3 AURORA trial: myastheniagravis.study.scien…

Tune in tomorrow at 9:30 am ET to hear our fireside chat at the Needham Virtual Healthcare Conference. Listen to the webcast here: bit.ly/3PXeHqj #celltherapy #autoimmunity

Tune in tomorrow at 9:30 am ET to hear our fireside chat at the Needham Virtual Healthcare Conference. Listen to the webcast here: bit.ly/3PXeHqj #celltherapy #autoimmunity

Last month we participated in Cantor's #RareDiseaseDay webinar series discussing #Myositis, a rare set of pathogenic autoantibody-driven diseases characterized by inflammation and muscle weakness that impacts ~80,000 people in the U.S. Learn more here: bit.ly/4sIgQEf

Our team is on the ground at the International Myositis Society 6th Global Conference on Myositis kicking off today. Come see our posters and hear more about our work in #Myositis. View our posters: bit.ly/3NwD2Cv Learn more: bit.ly/4sIgQEf #RareDisease

We are at the @MDAorg congress this week. Come see our poster to hear more about our work in #myastheniagravis which was recently published in Nature Medicine! This will be our first time presenting this at a medical meeting. See our publications here: bit.ly/4ucQQCG

Today we reported full year 2025 financial results and provided a business update. Full press release: bit.ly/4cClHSW #celltherapy #autoimmunity